Stockscreener 앱 받기
0.00
100.00%
-123.96
Nuvalent Inc 주식(NUVL)의 최신 뉴스
NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? - Stocktwits
GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition - marketscreener.com
GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition, Bloomberg Reports - marketscreener.com
GSK Commences Six-Part Dollar Bond Sale to Help Fund Nuvalent Acquisition - marketscreener.com
GSK Launches Six-Part Dollar Bond Sale to Support Nuvalent Acquisition Financing, Bloomberg Reports - marketscreener.com
Nuvalent, Inc. (NUVL) Stock Analysis: What Investors Need to Know About This $9.81 Billion Biotech Player - DirectorsTalk Interviews
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK - Eastern Progress
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring the Biotech’s Steady Path with a $9.81 Billion Market Cap - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL) Stock Analysis: Evaluating Growth Potential Amidst a Steady Market Position - DirectorsTalk Interviews
Nuvalent (NUVL) Results Review: EPS Does Not Reach the Reported Estimate in the Latest Reading; Latest Reaction: The Immediate Price Response Is Limited for the Current SessionEarnings Deceleration Risk - vinanet.vn
Nuvalent Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Nuvalent, Inc. (NUVL) Stock Analysis: Steady at $123.96 with Phase 2 Clinical Trials on the Horizon - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL) Stock Analysis: Navigating Biotech’s Uncharted Waters with Zero Upside - DirectorsTalk Interviews
Equity in earnings of Nuvalent, Inc. Class A – LS:A3CWDU - TradingView
Nuvalent Inc (NUVL) Stock Analysis & Forecast - TradingKey
Nuvalent Inc (NUVL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of Nuvalent, Inc. Class A – LS:A3CWDU - TradingView
Nuvalent, Inc. (NUVL) Stock Analysis: A $9.79 Billion Biotech Game-Changer Facing Analyst Consensus - DirectorsTalk Interviews
Nuvalent Inc (NUVL) Institutional Confidence - TradingKey
Nuvalent, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Nuvalent Inc (NUVL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NUVL|Nuvalent Inc|Price:123.965| - TradingKey
Nuvalent Inc (NUVL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvalent Inc (NUVL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvalent Inc (NUVL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvalent Inc (NUVL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvalent Inc (NUVL) Cash Flow - TradingKey
Nuvalent, Inc. Class A Revenue Breakdown – LS:A3CWDU - TradingView
GSK Lands Its First Lung Cancer Drug Days After Nuvalent Deal Closes - finance.biggo.com
FDA Approves NSCLC Treatment Acquired by GSK in Nuvalent Deal - Contract Pharma
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet - Yahoo Finance
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC - Yahoo Finance
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $116 to $155 - Moomoo
GSK's $10.6B Nuvalent acquisition delivers first FDA approval ahead of schedule - The Business Journals
GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal - Fierce Pharma
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer - PR Newswire
Bernstein initiates coverage of Nuvalent (NUVL) with outperform recommendation - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasd - Supply Chain Digital
How Nuvalent Inc. (NUVL) Affects Rotational Strategy Timing - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Wall Street Zen Upgrades Nuvalent (NASDAQ:NUVL) to Sell - MarketBeat
Deerfield group reports 0% ownership in Nuvalent (NUVL) Class A shares - Stock Titan
Deerfield holders cash out of Nuvalent (NUVL) at $124 per share - Stock Titan
Nuvalent, Inc.(NasdaqGM: ) dropped from Russell 2500 Growth Index - marketscreener.com
Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Nuvalent, Inc.(NasdaqGM: ) dropped from Russell 2000 Defensive Index - marketscreener.com
Form 4 Nuvalent Inc For: 15 July By Investing.com - Investing.com Canada
Nuvalent, Inc. (NUVL) director exits holdings in $124 GSK merger - Stock Titan
Nuvalent, Inc. (NUVL) CFO details tender offer and award cash-outs - Stock Titan
Form 4 Nuvalent Inc For: 15 July - Investing.com India
Nuvalent, Inc. (NUVL) director tenders stock in $124 GSK cash buyout - Stock Titan
Nuvalent (NUVL) director cashes out equity in GSK merger deal - Stock Titan
Nuvalent, Inc. (NUVL) director’s RSUs and options canceled for $124 cash rights in GSK merger - Stock Titan
GSK’s $124-per-share Nuvalent, Inc. (NUVL) deal reshapes CMO equity - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
Nuvalent, Inc. (NUVL) CEO equity converted in $124 GSK tender offer - Stock Titan
Nuvalent, Inc. (NUVL) officer exits via $124-per-share cash tender - Stock Titan
Nuvalent, Inc. (NUVL) CSO swaps shares and options for $124 cash in GSK deal - Stock Titan
Nuvalent (NUVL) CLO exits equity via $124-per-share GSK tender offer and merger - Stock Titan
Nuvalent (NUVL) director equity cashed out in $124 GSK buyout - Stock Titan
Nuvalent (NASDAQ: NUVL) director logs $124 tender-offer disposals - Stock Titan
GlaxoSmithKline LLC completed the acquisition of Nuvalent, Inc. from Deerfield Management Company, L.P. and others. - marketscreener.com
GSK completes $10.6 billion acquisition of Nuvalent By Investing.com - Investing.com India
GSK Completes Acquisition of Nuvalent to Expand Oncology Pipeline - GuruFocus
GSK Completes $10.6 Billion Acquisition of Nuvalent - Moomoo
Nuvalent (NASDAQ: NUVL) moves to remove Class A stock from Nasdaq - Stock Titan
0.75%
3.18%
자본화:
|
볼륨(24시간):